Want to see PCVX full AI Analyst Report?
PCVX Stock Chart & Stats
$61.09
-$0.98(-1.76%)
At close: 4:00 PM EDT
$61.09
-$0.98(-1.76%)
Day’s Range― - ―
52-Week Range$39.87 - $90.75
Previous CloseN/A
Volume1.12M
Average Volume (3M)2.87M
Market Cap
$10.01B
Enterprise Value$7.03B
Total Cash (Recent Filing)$1.49B
Total Debt (Recent Filing)$115.44M
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Nov 09, 2026EPS Estimate
-2.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.64
Shares Outstanding157,389,650
10 Day Avg. Volume5,711,528
30 Day Avg. Volume2,868,158
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio-9.38
Enterprise Value/Market Cap0.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-8.12K
Enterprise Value/Ebitda-6.70
Forecast
1Y Price Target
$117.30Price Target Upside92.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-8.3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase 3 ValidationSuccessful pivotal Phase 3 results materially strengthen Vaxcyte’s clinical and regulatory position. Broad immune responses, a favorable safety profile, and immunobridging support the planned BLA and improve the candidate’s prospects for differentiated protection in adult pneumococcal vaccination.
Financial FlexibilityVery low leverage and a substantial equity base provide financial flexibility while Vaxcyte advances its clinical pipeline. This balance-sheet capacity can support development and regulatory activities, although continued losses mean the strength depends on disciplined capital use and future funding access.
Experienced Vaccine LeadershipAdding a senior vaccines executive with relevant clinical and regulatory experience strengthens execution as Vaxcyte transitions from late-stage development toward potential licensure. Leadership expertise is particularly valuable for coordinating remaining trials, regulatory preparation, and eventual commercialization planning.
Bears Say
Pre-revenue Business ModelThe absence of reported revenue means Vaxcyte has not yet demonstrated commercial demand or internally generated funding from its vaccine candidates. Until a product is approved and launched, the company remains dependent on capital markets and successful clinical and regulatory execution.
Accelerating LossesRapidly expanding losses indicate that operating expenses are rising substantially ahead of commercialization. Persistent negative earnings can erode the equity base, increase reliance on external financing, and reduce strategic flexibility if development timelines extend or additional trials require greater investment.
Heavy Cash ConsumptionLarge and worsening cash outflows create an ongoing requirement to fund research, trials, and regulatory work through available liquidity or new financing. This raises execution risk over the next several quarters and may lead to further shareholder dilution or additional obligations.
Vaxcyte News
PCVX FAQ
What was Vaxcyte, Inc.’s price range in the past 12 months?
Vaxcyte, Inc. lowest stock price was $39.87 and its highest was $90.75 in the past 12 months.
What is Vaxcyte, Inc.’s market cap?
Vaxcyte, Inc.’s market cap is $10.01B.
When is Vaxcyte, Inc.’s upcoming earnings report date?
Vaxcyte, Inc.’s upcoming earnings report date is Nov 09, 2026 which is in 21 days.
How were Vaxcyte, Inc.’s earnings last quarter?
Vaxcyte, Inc. released its earnings results on Aug 05, 2026. The company reported -$1.97 earnings per share for the quarter, beating the consensus estimate of -$2.056 by $0.086.
Is Vaxcyte, Inc. overvalued?
According to Wall Street analysts Vaxcyte, Inc.’s price is currently Undervalued.
Does Vaxcyte, Inc. pay dividends?
Vaxcyte, Inc. does not currently pay dividends.
What is Vaxcyte, Inc.’s EPS estimate?
Vaxcyte, Inc.’s EPS estimate is -2.11.
How many shares outstanding does Vaxcyte, Inc. have?
Vaxcyte, Inc. has 157,389,650 shares outstanding.
What happened to Vaxcyte, Inc.’s price movement after its last earnings report?
Vaxcyte, Inc. reported an EPS of -$1.97 in its last earnings report, beating expectations of -$2.056. Following the earnings report the stock price went up 5.311%.
Which hedge fund is a major shareholder of Vaxcyte, Inc.?
Currently, no hedge funds are holding shares in PCVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vaxcyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$117.30 (92.01% Upside)
$117.30 (92.01% Upside)
Blogger Sentiment
Bullish
PCVX Sentiment 86%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 22.7%
Last 30 Days ▲ 22.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.95%
12-Months-Change
Fundamentals
Return on Equity
-37.57%
Trailing 12-Months
Asset Growth
-5.06%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Vaxcyte, Inc.
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
PCVX Stock 12 Month Forecast
Average Price Target
$117.30
▲(92.01% Upside)
Technical Analysis
Novavax
―
ImmunityBio
―
Twist Bioscience
―
Vir Biotechnology
―
Maravai Lifesciences Holdings
―
Ownership Overview
0.78% Insiders
36.12% Mutual Funds
0.03% Other Institutional Investors
45.83% Public Companies and
Individual Investors